Skip to main content
. 2022 Nov 17;12(11):1563. doi: 10.3390/brainsci12111563

Table 1.

Baseline characteristics of the cohort at T0 and T1.

T0 T1 p
Age 50.8 (±11.1) -- --
Female Sex, (n, %) 55 (70.5%) -- --
Clinical Improvement, (n, %) -- 48 (61.5%) --
MIDAS Score (±SD) 77.43 (±52.8) 41.16 (±39.4) 0.0001
Crises per Month (±SD) 21.51 (±6.59) 12.65 (±8.31) 0.001
Migraine Type:

  • Chronic (n, %)

  • Episodic (n, %)

  • 75 (100%)

  • 0 (0.0%)

  • 33 (44.0%)

  • 42 (56.0%)

 0.0001
BS-11 (±SD) 9.17 (±1.36) 7.53 (±2.02) 0.0001
PPI (±SD) 4.16 (±0.81) 3.17 (±1.15) 0.0001
BRS-6 (±SD) 4.36 (±0.75) 3.39 (±1.25) 0.0001
HIT-6 (±SD) 18.04 (±2.99) 14.67 (±4.06) 0.0001
Drug Prophylaxis at T0 (n, %)

  • Topiramate

  • Valproic Acid

  • Amitriptyline

  • Propranolol

  • Gabapentin

  • Lamotrigin

  • Pregabalin

  • No therapies

  • 20 (26.7%)

  • 5 (6.7%)

  • 33 (44%)

  • 4 (5.3%)

  • 5 (6.4%)

  • 1 (1.3%)

  • 2 (2.7%)

  • 5 (6.67%)

 -- --
Drug Treatment of Attacks (n,%)

  • NSAIDS

  • Triptans

  • Indomethacin

  • Paracetamol

  • 7 (9.3%)

  • 35 (46.67%)

  • 11 (13.3%)

  • 3 (4.0%)

 -- --
OCI-R (IQR) 1 (2) 0 (2) 0.0001
OCI-R

  • Normal

  • Borderline

  • Discomfort

  • Pathologic

  • 26 (34.7%)

  • 21 (28.0%)

  • 11 (14.7%)

  • 17 (22.7%)

  • 42 (56.0%)

  • 11 (14.7%)

  • 10 (13.3%)

  • 12 (16.0%)

 0.0001